With 0.59 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.17 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.905 whereas the lowest price it dropped to was $4.76. The 52-week range on SLRN shows that it touched its highest point at $29.33 and its lowest point at $3.36 during that stretch. It currently has a 1-year price target of $11.40. Beta for the stock currently stands at 2.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SLRN was up-trending over the past week, with a rise of 11.44%, but this was down by -30.43% over a month. Three-month performance surged to 17.92% while six-month performance fell -40.32%. The stock lost -82.19% in the past year, while it has lost -34.72% so far this year. A look at the trailing 12-month EPS for SLRN yields -3.06 with Next year EPS estimates of -2.10. For the next quarter, that number is -0.80. This implies an EPS growth rate of 45.60% for this year and 28.97% for next year.
Float and Shares Shorts:
At present, 97.87 million SLRN shares are outstanding with a float of 64.18 million shares on hand for trading. On 2024-07-31, short shares totaled 7.22 million, which was 729.0000000000001 higher than short shares on 1719532800. In addition to Ms. Melanie Gloria B.S.N. as the firm’s Chief Operating Officer, Ms. Mina Kim serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 1.01957 of SLRN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, SLRN reported revenue of $0.0 and operating income of -$93025000.0. The EBITDA in the recently reported quarter was -$92909000.0 and diluted EPS was -$0.86.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SLRN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, SLRN has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and SLRN currently yields $0.00. In the past year, SLRN’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, SLRN has a current buyback yield of $0.11. This was $0.11 for the TTM, and it was $– for the past five years.
